News | July 18, 2022
China Pharma submits plan of compliance to NYSE American
The company was directed to submit a plan of compliance by July 15, 2022
The company was directed to submit a plan of compliance by July 15, 2022
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
ICRA expects the OPM of the sample set to moderate to 20.2% in FY2023 from 21.5% in FY2022.
Orion to receive an upfront payment of USD 290 million
Upgrades and global expansion provide additional control, visibility, reliability and recovery for patient-critical, time-and temperature-sensitive products
To strengthen the integrated human-centric preventive health screening ‘Phygital’ ecosystem in India
Mittal will be driving expansion of the provider network across India
She joins Enveda from Gilead Sciences
Advancing to IND-enabling studies with multiple drug candidates
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
Subscribe To Our Newsletter & Stay Updated
